Survival of patients treated with sir-spheres more than double that of patients who received best supportive care, benefit rivals that found with new biological agents, authors note
The results of a matched-pair comparison of patients with metastatic colorectal cancer predominately affecting the liver, for whom all chemotherapy options had been exhausted, showed that the addition of radioembolization using SIR-Spheres significantly prolonged survival compared with best supportive care (BSC) alone.1
The study, published in October’s edition ofCardiovascular and Interventional Radiology, showed that median overall survival was more than doubled in patients receiving radioembolization plus BSC versus BSC alone: 8.3 months vs. 3.5 months (hazard ratio [HR] 0.26; 95% confidence interval 0.15—0.48; P0.001).a multivariate analysis confirmed that radioembolization was the only significant predictor for prolonged survival among all the baseline parameters investigated (HR 0.30; 95% CI 0.16—0.55; P0.001).“Radioembolization significantly prolonged overall survival compared with supportive care alone in a well-matched cohort of patients with extensive, liver-dominant chemotherapy refractory disease for whom there are limited treatment options,” said Prof. Jens Ricke, Director of Radiologyand Nuclear Medicine at the University Hospital of Magdeburg, Germany,and senior author of the study. “The evidence suggests that radioembolization should be considered as a treatment option for patients with liver-only or liver-dominant colorectal metastases who have failed or are intolerant of chemotherapy.”
For Further Information:
Contact:
Vichai Lertritchai, Mileage (Thai) Co., Ltd. (02) 632-8356
Email: [email protected]
Email: [email protected]